Zoliflodacin

Candidate

CAS: 1620458-09-4

Sample Stock:

Zoliflodacin is a groundbreaking, first-in-class oral antibiotic specifically developed to address the global threat of antimicrobial-resistant gonorrhea. It received U.S. Food and Drug Administration (FDA) approval on December 11, 2025, for the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older weighing at least 35 kg.

Related Information

Purity:98%+

Registration:GMP/DMF

Biological Profile

Associated Conditions

gonorrhea

Key Intermediates

9 Items

Name	CAS No.	MDL No.
2,3,4-Trifluorobenzaldehyde	161793-17-5	MFCD00061230
2,6-Dimethylmorpholine, (2R,6R)-	171753-74-5	MFCD18250270
5-(1,3-Dioxolan-2-yl)-2,3,4-trifluorobenzaldehyde oxime	1620459-32-6	-
(S)-6,7-Difluoro-3-(4-methyl-2-oxooxazolidin-3-yl)benzo[d]isoxazole-5-carbaldehyde	1802089-88-8	-
3-Chloro-6,7-difluorobenzo[d]isoxazole-5-carbaldehyde	1223451-46-4	-
2,6-Dimethylmorpholine, cis-	2098200-15-6	MFCD00078428
2-(2,3,4-Trifluorophenyl)-1,3-dioxolane	773102-28-6	-
(4S)-3-[5-(1,3-Dioxolan-2-yl)-6,7-difluoro-1,2-benzisoxazol-3-yl]-4-methyl-2-oxazolidinone	1802089-90-2	-
6-[(2R,6R)-2,6-Dimethyl-4-morpholinyl]-7-fluoro-3-[(4S)-4-methyl-2-oxo-3-oxazolidinyl]-1,2-benzisoxazole-5-carboxaldehyde	1802089-86-6	-